| Application no. and date | 11845186.3 (espacenet) (Federated) (European Patent Register), 20111202 | | Patent/reg. no. and date | DK/EP 2646031, 20170222 | | Publication date | 20131009 | | Priority no. and date | US 419395 P, 20101203 | | EP pub. no. and date |
EP 2646031 20131009 | | Effective date | | | Applicant/owner | Orexigen Therapeutics, Inc., 3344 North Torrey Pines Court, Suite 200
La Jolla, CA 92037, US | | Applicant ref. no. | 61568DK01 | | Inventor | DUNAYEVICH, Eduardo, 1030 Deep Wood Drive
Westlake Village, CA 91362, US,
FLANAGAN, Shawn, 14083 Via Corsini
San Diego
CA 92128, US | | Representative | Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup | | Opponent | | | IPC Class | A61K 31/137 (2006.01) , A61K 31/485 (2006.01) , A61P 3/04 (2006.01) | | Title | Forøget lægemiddelbiotilgængelighed i naltrexonterapi | | Int. application no. | US2011063177 | | Int. publication no. | WO2012075459 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
